Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
More News related to Upgrades
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
Lazard Capital upgrades Progenics Pharmaceuticals (Nasdaq: PGNX) from Hold to Buy.
Related Categories
UpgradesStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
